Associated Genetic Biomarkers
Catenin (cadherin-associated protein), alpha 1, 102kDa (CTNNA1) is a gene that encodes a protein for which the biological function is unknown. Missense mutations, nonsense mutations, silent mutations, whole gene deletions, frameshift deletions and insertions, and in-frame insertions are observed in cancers such as endometrial cancer, intestinal cancer, and stomach cancer.
CTNNA1 is altered in 0.72% of all cancers with breast invasive ductal carcinoma, colon adenocarcinoma, lung adenocarcinoma, endometrial endometrioid adenocarcinoma, and melanoma having the greatest prevalence of alterations .
The most common alterations in CTNNA1 are CTNNA1 Mutation (1.34%), CTNNA1 Amplification (0.14%), CTNNA1 Loss (0.09%), CTNNA1 Fusion (0.08%), and CTNNA1 I213V (0.06%) .
CTNNA1 status serves as an inclusion eligibility criteria in 1 clinical trial, of which 1 is open and 0 are closed. Of the trial that contains CTNNA1 status as an inclusion criterion, 1 is phase 2/phase 3 (1 open).
Trials with CTNNA1 status in the inclusion eligibility criteria most commonly target medulloblastoma .
The most frequent alterations to serve as inclusion eligibility criteria are CTNNA1 Expression and CTNNA1 Mutation .
Radiation therapy is the most frequent therapy in trials with CTNNA1 as an inclusion criteria .
Significance of CTNNA1 in Diseases
CTNNA1 is an inclusion criterion in 1 clinical trial for medulloblastoma, of which 1 is open and 0 are closed. Of the trial that contains CTNNA1 status and medulloblastoma as inclusion criteria, 1 is phase 2/phase 3 (1 open) .
2. The UniProt Consortium. UniProt: a worldwide hub of protein knowledge. Nucleic Acids Research. 2019;47:D506-D515.
3. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.